We can however anticipate low shots in some situations
GLP-1 drugs research: summary GLP1 drugs may move beyond diabetes and weight loss into multidisease therapies This could significantly increase the number and profile of users, including nonobese and older populations Innovations such as oral GLP1s may further accelerate uptake and accessibility For food and beverage, the shift needs to be watched closely to understand behaviour change, consumption patterns and nutritional needs GLP-1s started life as diabetes medications, then took the world by storm for treating obesity
At MFX, in collaborative work done with AstraZeneca Sweden in 2024, co-conducted by Nicholas Akosa (MFX Head of Fields Applications), we demonstrate successful & comparable expansion & phenotype as well as higher viability of T-regs in our low-volume MFX-12 bioreactor vs
Key Capabilities: Injection tracking: Quick and simple logging
[DOI] [PMC free article] [PubMed] [Google Scholar] Llewellyn-Smith IJ, Reimann F, Gribble FM, Trapp S